Forward-Looking Statements & Pro-Forma Financial Measures

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this presentation are based on Quanterix’ expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

To supplement the Company's financial statements presented on a GAAP basis, the Company has provided certain pro-forma financial measures. Management uses these pro-forma measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such measures are important in comparing current results with other period results and are useful to investors and financial analysts in assessing the Company’s operating performance. The pro-forma financial information presented here should be considered in conjunction with, and not as a substitute for the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these pro-forma measures to their most directly comparable GAAP financial measures set forth in the appendix of this presentation.
Q2 2022 Pro-Forma Results

<table>
<thead>
<tr>
<th></th>
<th>Q2 2021</th>
<th>Q2 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue $</td>
<td>25.4</td>
<td>23.5</td>
</tr>
<tr>
<td>GM $ *</td>
<td>12.0</td>
<td>6.6</td>
</tr>
<tr>
<td>GM % *</td>
<td>47.5%</td>
<td>28.3%</td>
</tr>
<tr>
<td>Operating Loss</td>
<td>-13.7</td>
<td>-25.0</td>
</tr>
<tr>
<td>Operating Loss as % of Revenue</td>
<td>-53.9%</td>
<td>-106.2%</td>
</tr>
</tbody>
</table>

*Reconciliation of Pro-Forma Gross Margin included on slide 7
## 1H 2022 Pro-Forma Results

<table>
<thead>
<tr>
<th></th>
<th>1H 2021</th>
<th>1H 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue $</td>
<td>52.6</td>
<td>53.1</td>
</tr>
<tr>
<td>GM $ *</td>
<td>26.7</td>
<td>19.3</td>
</tr>
<tr>
<td>GM % *</td>
<td>50.7%</td>
<td>36.5%</td>
</tr>
<tr>
<td>Operating Loss</td>
<td>-23.5</td>
<td>-43.1</td>
</tr>
<tr>
<td>Operating Loss as % of Revenue</td>
<td>-44.6%</td>
<td>-81.3%</td>
</tr>
</tbody>
</table>

*Reconciliation of Pro-Forma Gross Margin included on slide 7

### Revenue Breakdown

<table>
<thead>
<tr>
<th></th>
<th>1H 2021</th>
<th>1H 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTRUMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSUMABLES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACCELERATOR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER SERVICES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Mix</th>
<th>22%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45%</td>
<td>23%</td>
</tr>
<tr>
<td></td>
<td>10%</td>
<td></td>
</tr>
</tbody>
</table>

### Revenue Breakdown by Segment

- **1H 2021**: Instruments: 12.8, Consumables: 24.1, Accelerator: 7.8, RADx: 3.2, Others Services: 4.6
- **Q2 2022**: Instruments: 11.8, Consumables: 23.6, Accelerator: 12.1, RADx: 3.2, Others Services: 5.5

- Instruments: -8%
- Consumables: -2%
- Accelerator: +55%
- RADx: -100%
- Others Services: +20%
Q1’22 to Q2 ‘22 Pro-Forma Gross Margin Contribution

*Reconciliation of Pro-Forma Gross Margin included on slide 7*
Q1’22 to Q2 ‘22 Pro-Forma Operating Expense

Reconciliation of Pro-Forma Operating Expense included on slide 7
Reconciliation of GAAP to Pro Forma

<table>
<thead>
<tr>
<th></th>
<th>2022 Three months ended June 30</th>
<th>2021</th>
<th>2022 Six months ended June 30</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross profit</td>
<td>8,711</td>
<td>13,874</td>
<td>23,270</td>
<td>30,223</td>
</tr>
<tr>
<td>Distribution Costs (Note 1)</td>
<td>(2,065)</td>
<td>(1,827)</td>
<td>(3,929)</td>
<td>(3,562)</td>
</tr>
<tr>
<td>Pro forma gross profit</td>
<td>6,646</td>
<td>12,047</td>
<td>19,341</td>
<td>26,661</td>
</tr>
<tr>
<td>GAAP gross margin %</td>
<td>37.1%</td>
<td>54.7%</td>
<td>43.9%</td>
<td>57.5%</td>
</tr>
<tr>
<td>Pro forma gross margin %</td>
<td>28.3%</td>
<td>47.5%</td>
<td>36.5%</td>
<td>50.7%</td>
</tr>
<tr>
<td>GAAP total operating expenses</td>
<td>33,670</td>
<td>27,542</td>
<td>66,416</td>
<td>53,680</td>
</tr>
<tr>
<td>Distribution Costs (Note 1)</td>
<td>(2,065)</td>
<td>(1,827)</td>
<td>(3,929)</td>
<td>(3,562)</td>
</tr>
<tr>
<td>Pro forma total operating expenses</td>
<td>31,605</td>
<td>25,715</td>
<td>62,487</td>
<td>50,118</td>
</tr>
<tr>
<td>GAAP loss from operations</td>
<td>(24,959)</td>
<td>(13,668)</td>
<td>(43,146)</td>
<td>(23,457)</td>
</tr>
<tr>
<td>Pro forma loss from operations</td>
<td>(24,959)</td>
<td>(13,668)</td>
<td>(43,146)</td>
<td>(23,457)</td>
</tr>
</tbody>
</table>

Note 1: Distribution costs, which include freight and other activities costs associated with product shipments, net of charges passed on to the customer, are captured within operating expenses in our consolidated statements of operations. During the three and six months ended June 30, 2022, we incurred $2.1 million and $3.9 million, respectively, of distribution costs recorded within operating expenses. During the three and six months ended June 30, 2021, we incurred $1.8 million and $3.6 million, respectively, of distribution costs recorded within operating expenses.
Scientific Validation Driving Adoption

2022 Advances

**Publications**
- Cumulative
- 2018: 409
- 2019: 677
- 2020: 1,120
- 2021: 1,224
- YTD 2022: 1,845

**Biomarkers**
- Cumulative
- 2018: 259
- 2019: 322
- 2020: 403
- 2021: 274
- YTD 2022: 518

**Instruments**
- Placements # of units placed
- 2018: 278
- 2019: 400
- 2020: 535
- 2021: 467
- YTD 2022: 798

Categories:
- Neurology
- Immunology & Oncology
- Infectious Diseases
- Others
Q2 2022 Revenue Stratification

**Geography:***
- NA: -5%
- Europe: 10%
- Asia: -31%

**Customer:***
- Pharma / CROs: -6.2%
- Academia: -8.3%

**Diseases:***
- Neurology: -14%
- Oncology**: 96%
- Others: -34%

**Products & Services:***
- Consumables: -29%
- Accelerator: 66%
- Instruments: -4%

**YOY Growth:***
- NA: -5%
- Europe: 10%
- Asia: -31%
- Pharma / CROs: -6.2%
- Academia: -8.3%
- Neurology: -14%
- Oncology**: 96%
- Others: -34%
- Consumables: -29%
- Accelerator: 66%
- Instruments: -4%

**Incl. Immunology & Inflammation**
The first pTau-181 plasma test released for clinical use in the U.S

Results of the validation study presented at 2022 Alzheimer’s Association International Conference

July 27, 2022

Quanterix announced the validation of a laboratory developed test to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer’s disease (AD)

**Background**
- A quantitative immunoassay intended for the measurement of pTau-181 concentration in human plasma
- The test results are intended to be used in adults presenting with cognitive impairment who are being evaluated for AD and must be interpreted in conjunction with other diagnostic tools.

**Detection**
- Phospho-tau isoforms are uniquely positioned to anchor efforts to evaluate and diagnose AD pathology.
- Proteins specific for AD can serve to increase the sensitivity and specificity of a test that incorporates less specific blood-based markers of brain health, such as amyloid beta and neurofilament light chain (NfL).

A menu of assays covering these markers, including in multiplex formats, has been developed on Quanterix’ ultrasensitive platforms.
Increasing Investment in Neurodegenerative Disease

Growth in neurodegenerative disease research and drug development investments

Trends in NIH Funding: 2017 - 2022

Alzheimer's Disease

- 2017: $1,000
- 2018: $2,000
- 2019: $3,000
- 2020: $4,000
- 2021: $5,000
- 2022 Est.: $6,000

- Increase: 401%

Non-AD Neurological Disease

- ALS
- MS
- Parkinson's
- TBI

- 2017: $100
- 2018: $200
- 2019: $300
- 2020: $400
- 2021: $500
- 2022 Est.: $600

- Increase: 72%, 130%, 106%, 177%

Consistent and significant increases in NIH-funded neurodegenerative disease research

Source: clinicaltrials.gov

Promising late-stage Alzheimer’s Drug Trials

<table>
<thead>
<tr>
<th>Company</th>
<th>Drug</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogen</td>
<td>Adutemod</td>
<td>Phase 4, Approved</td>
</tr>
<tr>
<td>Lilly</td>
<td>Donanemod</td>
<td>Phase 3, Submitted</td>
</tr>
<tr>
<td>Eisai</td>
<td>Lecanemod</td>
<td>Phase 3, Submitted</td>
</tr>
<tr>
<td>Roche</td>
<td>Gantenerumod</td>
<td>Phase 3, BTD Granted</td>
</tr>
<tr>
<td>JSJ</td>
<td>JNJ-63733657</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Abbvie/Alector</td>
<td>AL002</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

Important advances in late-stage AD, MS, & ALS trials
Quanterix Enabling the Full Drug Development Continuum

Simoa technology accelerating drug approval from basic research to post-market clinical studies

Drug Discovery | Pre-Clinical | Phase I | Phase II | Phase III | FDA Review | Phase IV

Volunteers Needed

- Safety
- Safety & Effectiveness
- Effectiveness & Side Effects
- Safety & Optimal Use

Early Phase Biomarker Research
Who: Academics, Pharma, CROs
QTRX Products: Instruments, home brew kits and assay development services for new markers

Translational Biomarker Research
Who: Pharma, CROs, Research Consortia
QTRX Products: Instruments, consumables, assay development & research testing services

Biomarker Endpoints, Monitoring & Dx
Who: Pharma, CROs, Treating Physicians
QTRX Products: Instruments, consumables, research and clinical laboratory testing services

Examples of recent drug trials and featuring key QTRX products

- Phase II: Simoa pTau 217 correlated to reduction in amyloid PET (Lilly)
- Phase III: Simoa NFL correlated to disease activity (Novartis, Biogen)
- Phase IV: Simoa pTau 181 correlated to reduction in amyloid PET (Biogen)
Patient Selection Strategy Can Accelerate Drug Approval

Simoa Blood-Based Patient Screening Can Reduce Trial Costs & Accelerate Enrollment

Representative Clinical Trial Design

Late-Stage Clinical Trial
- Disease modifying therapy for Alzheimer’s

Inclusion Criteria
- Cognitively unimpaired
- PET+ (various centiloid cutoffs)

Target Enrollment
- 3,000 subjects
- 1% positive screen rate

300,000 potential subjects screened

PET vs Simoa

$5,000 PET scan
$1.5B trial enrollment costs
Invasive & inaccessible

✓ $100 Simoa assay
✓ 50X reduction in enrollment costs
✓ Simple & non-invasive

Quanterix

Simoa blood-based testing can enable non-invasive, cost-effective identification of patients more likely to benefit from disease modifying therapy, accelerating trial enrollment and increasing probability of approval.